Recently, an association between uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphisms and pazopanib-induced liver toxicity was observed.[15] The UGT1A1 enzyme is inhibited by pazopanib, and patients carrying the UGT1A1∗28 allele (also known as TA7, where TA6 represents the wild type allele) have a risk of hyperbilirubinemia. This evidence concerns the gene UGT1A1 and Hyperbilirubinemia.